THE NICKLES GROUP, LLC

Lobbying for OMEROS CORPORATION · Biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Washington · House · Senate · posted Apr 8, 2026

Lobbying activity 2

Medicare/Medicaid

Monitored separate payment policy for nonopioid alternatives. Monitored issues involving rare disease therapies.

Health Issues

Monitored issues related to rare pediatric disease and Priority Review Vouchers (PRVs).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.